Thomas Michael Perone - 08 Apr 2022 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
General Counsel, Secretary
Signature
/s/ Danielle Mann for Thomas Perone by PoA
Issuer symbol
OVID
Transactions as of
08 Apr 2022
Net transactions value
$0
Form type
4
Filing time
12 Apr 2022, 17:30:42 UTC
Previous filing
04 Feb 2022
Next filing
27 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +25,399 $0.000000 25,399 08 Apr 2022 Common Stock 25,399 $3.22 Direct F1
transaction OVID Stock Option (Right to Buy) Award $0 +10,000 $0.000000 10,000 08 Apr 2022 Common Stock 10,000 $3.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date.